Clinuvel Pharmaceuticals Ltd
ASX:CUV
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Price:
14.86 AUD
Market Closed
Updated:
May 5, 2024
Clinuvel Pharmaceuticals Ltd
Net Income (Common)
|
Clinuvel Pharmaceuticals Ltd
Net Income (Common) Peer Comparison
Comparables:
IMM
MSB
CSL
TLX
PYC
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Net Income (Common)
AU$30.2m
|
CAGR 3-Years
13%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Immutep Ltd
ASX:IMM
|
Net Income (Common)
-AU$40.5m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-12%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Net Income (Common)
-$73.1m
|
CAGR 3-Years
9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Net Income (Common)
$2.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Net Income (Common)
AU$5.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Net Income (Common)
-AU$21.6m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-23%
|
See Also
What is Clinuvel Pharmaceuticals Ltd's Net Income (Common)?
Net Income (Common)
30.2m
AUD
30.2m
AUD
Based on the financial report for Dec 31, 2023, Clinuvel Pharmaceuticals Ltd's Net Income (Common) amounts to 30.2m AUD.
What is Clinuvel Pharmaceuticals Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
14%
14%
Over the last year, the Net Income (Common) growth was 14%. The average annual Net Income (Common) growth rates for Clinuvel Pharmaceuticals Ltd have been 13% over the past three years , 14% over the past five years .
You don't have any saved screeners yet
